# Annuobode

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/annuobode

- Industry: Biotechnology
- Headquarters: Ningbo, China
- Website: www.anobiomed.com
- Latest round: Series A (Apr 19, 2018)
- Investors on record: 1

## About

Established in 2017 and based in Ningbo, China, Annuobode is a biopharmaceutical company that develops tumor immuno-antibody drugs and gene-based drugs. The company has applied for a number of registered patents covering CAR-T, PD1 multiple tumor immunotherapy areas. The core team members are from University of Oklahoma, Shanghai Institute of Biochemistry and Cellular Research of Chinese Academy of Sciences and other universities and research institutes, and are proficient in antibody engineering, immunology, virology and other disciplines. The company has about 1000m2 GMP standard cell preparation workshop, molecular biology laboratory in Malaysia, Israel and other countries also have CAR-T multi-center clinical trial translation base. In April 2023, the company closed a round of venture funding.

The company mainly develops anti-cancer and gene drugs in the field of CAR-T cells, TCR-T and CAR-NK. It also has an antibody screening platform, a clinical lentivirus production platform and a cell gene editing platform.

## Funding rounds

- Series A, Apr 19, 2018 — Sharelink Capital

## Investors

- Sharelink Capital (https://capitalatlas.ai/funds/sharelink-capital) — Series A